Phosphorylated α-synuclein in Parkinson's disease

Yu Wang; Min Shi; Kathryn A. Chung; Cyrus P. Zabetian; James B. Leverenz; Daniela Berg; Karin Srulijes; John Q. Trojanowski; Virginia M.Y. Lee; Andrew D. Siderowf; Howard Hurtig; Irene Litvan; Mya C. Schiess; Elaine R. Peskind; Masami Masuda; Masato Hasegawa; Xiangmin Lin; Catherine Pan; Douglas Galasko; David S. Goldstein; Poul Henning Jensen; Hui Yang; Kevin C. Cain; Jing Zhang

doi:10.1126/scitranslmed.3002566

Phosphorylated α-synuclein in Parkinson's disease

Yu Wang, Min Shi, Kathryn A. Chung, Cyrus P. Zabetian, James B. Leverenz, Daniela Berg, Karin Srulijes, John Q. Trojanowski, Virginia M.Y. Lee, Andrew D. Siderowf, Howard Hurtig, Irene Litvan, Mya C. Schiess, Elaine R. Peskind, Masami Masuda, Masato Hasegawa, Xiangmin Lin, Catherine Pan, Douglas Galasko, David S. GoldsteinPoul Henning Jensen, Hui Yang, Kevin C. Cain, Jing Zhang

Neurology

Research output: Contribution to journal › Article › peer-review

219 Scopus citations

Abstract

Phosphorylated α-synuclein (PS-129), a protein implicated in the pathogenesis of Parkinson's disease (PD), was identified by mass spectrometry in human cerebrospinal fluid (CSF). A highly sensitive and specific assay was established and used to measure PS-129 together with total α-synuclein in the CSF of patients with PD, other parkinsonian disorders such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), and healthy individuals (a total of ~600 samples). PS-129 CSF concentrations correlated weakly with PD severity and, when combined with total a-synuclein concentrations in CSF, contributed to distinguishing PD from MSA and PSP. Further rigorous validation in independent cohorts of patients, especially those where samples have been collected longitudinally, will determine whether the concentration of PS-129 in CSF will be useful for diagnosing PD and for monitoring PD severity and progression.

Original language	English (US)
Journal	Science translational medicine
Volume	4
Issue number	121
DOIs	https://doi.org/10.1126/scitranslmed.3002566
State	Published - Feb 15 2012

ASJC Scopus subject areas

General Medicine

Access to Document

10.1126/scitranslmed.3002566

Cite this

Wang, Y., Shi, M., Chung, K. A., Zabetian, C. P., Leverenz, J. B., Berg, D., Srulijes, K., Trojanowski, J. Q., Lee, V. M. Y., Siderowf, A. D., Hurtig, H., Litvan, I., Schiess, M. C., Peskind, E. R., Masuda, M., Hasegawa, M., Lin, X., Pan, C., Galasko, D., ... Zhang, J. (2012). Phosphorylated α-synuclein in Parkinson's disease. Science translational medicine, 4(121). https://doi.org/10.1126/scitranslmed.3002566

Wang, Y, Shi, M, Chung, KA, Zabetian, CP, Leverenz, JB, Berg, D, Srulijes, K, Trojanowski, JQ, Lee, VMY, Siderowf, AD, Hurtig, H, Litvan, I, Schiess, MC, Peskind, ER, Masuda, M, Hasegawa, M, Lin, X, Pan, C, Galasko, D, Goldstein, DS, Jensen, PH, Yang, H, Cain, KC & Zhang, J 2012, 'Phosphorylated α-synuclein in Parkinson's disease', Science translational medicine, vol. 4, no. 121. https://doi.org/10.1126/scitranslmed.3002566

@article{14ff8a8fc46e4bc98891b52233ecb0a0,

title = "Phosphorylated α-synuclein in Parkinson's disease",

abstract = "Phosphorylated α-synuclein (PS-129), a protein implicated in the pathogenesis of Parkinson's disease (PD), was identified by mass spectrometry in human cerebrospinal fluid (CSF). A highly sensitive and specific assay was established and used to measure PS-129 together with total α-synuclein in the CSF of patients with PD, other parkinsonian disorders such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), and healthy individuals (a total of ~600 samples). PS-129 CSF concentrations correlated weakly with PD severity and, when combined with total a-synuclein concentrations in CSF, contributed to distinguishing PD from MSA and PSP. Further rigorous validation in independent cohorts of patients, especially those where samples have been collected longitudinally, will determine whether the concentration of PS-129 in CSF will be useful for diagnosing PD and for monitoring PD severity and progression.",

author = "Yu Wang and Min Shi and Chung, {Kathryn A.} and Zabetian, {Cyrus P.} and Leverenz, {James B.} and Daniela Berg and Karin Srulijes and Trojanowski, {John Q.} and Lee, {Virginia M.Y.} and Siderowf, {Andrew D.} and Howard Hurtig and Irene Litvan and Schiess, {Mya C.} and Peskind, {Elaine R.} and Masami Masuda and Masato Hasegawa and Xiangmin Lin and Catherine Pan and Douglas Galasko and Goldstein, {David S.} and Jensen, {Poul Henning} and Hui Yang and Cain, {Kevin C.} and Jing Zhang",

year = "2012",

month = feb,

day = "15",

doi = "10.1126/scitranslmed.3002566",

language = "English (US)",

volume = "4",

journal = "Science translational medicine",

issn = "1946-6234",

publisher = "American Association for the Advancement of Science",

number = "121",

}

TY - JOUR

T1 - Phosphorylated α-synuclein in Parkinson's disease

AU - Wang, Yu

AU - Shi, Min

AU - Chung, Kathryn A.

AU - Zabetian, Cyrus P.

AU - Leverenz, James B.

AU - Berg, Daniela

AU - Srulijes, Karin

AU - Trojanowski, John Q.

AU - Lee, Virginia M.Y.

AU - Siderowf, Andrew D.

AU - Hurtig, Howard

AU - Litvan, Irene

AU - Schiess, Mya C.

AU - Peskind, Elaine R.

AU - Masuda, Masami

AU - Hasegawa, Masato

AU - Lin, Xiangmin

AU - Pan, Catherine

AU - Galasko, Douglas

AU - Goldstein, David S.

AU - Jensen, Poul Henning

AU - Yang, Hui

AU - Cain, Kevin C.

AU - Zhang, Jing

PY - 2012/2/15

Y1 - 2012/2/15

N2 - Phosphorylated α-synuclein (PS-129), a protein implicated in the pathogenesis of Parkinson's disease (PD), was identified by mass spectrometry in human cerebrospinal fluid (CSF). A highly sensitive and specific assay was established and used to measure PS-129 together with total α-synuclein in the CSF of patients with PD, other parkinsonian disorders such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), and healthy individuals (a total of ~600 samples). PS-129 CSF concentrations correlated weakly with PD severity and, when combined with total a-synuclein concentrations in CSF, contributed to distinguishing PD from MSA and PSP. Further rigorous validation in independent cohorts of patients, especially those where samples have been collected longitudinally, will determine whether the concentration of PS-129 in CSF will be useful for diagnosing PD and for monitoring PD severity and progression.

AB - Phosphorylated α-synuclein (PS-129), a protein implicated in the pathogenesis of Parkinson's disease (PD), was identified by mass spectrometry in human cerebrospinal fluid (CSF). A highly sensitive and specific assay was established and used to measure PS-129 together with total α-synuclein in the CSF of patients with PD, other parkinsonian disorders such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), and healthy individuals (a total of ~600 samples). PS-129 CSF concentrations correlated weakly with PD severity and, when combined with total a-synuclein concentrations in CSF, contributed to distinguishing PD from MSA and PSP. Further rigorous validation in independent cohorts of patients, especially those where samples have been collected longitudinally, will determine whether the concentration of PS-129 in CSF will be useful for diagnosing PD and for monitoring PD severity and progression.

UR - http://www.scopus.com/inward/record.url?scp=84863164994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863164994&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3002566

DO - 10.1126/scitranslmed.3002566

M3 - Article

C2 - 22344688

AN - SCOPUS:84863164994

SN - 1946-6234

VL - 4

JO - Science translational medicine

JF - Science translational medicine

IS - 121

ER -

Phosphorylated α-synuclein in Parkinson's disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this